Joined House of Lords: 28th January 2021
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Lord Kamall, and are more likely to reflect personal policy preferences.
Lord Kamall has not introduced any legislation before Parliament
Lord Kamall has not co-sponsored any Bills in the current parliamentary sitting
The Law Officers sit on the Parliamentary Business and Legislation Committee. As part of the process of approving a government Bill for introduction, as set out in the published Guide to Making Legislation, a legal issues memorandum is prepared for this Committee. This will set out all relevant legal issues.
Whether the Law Officers have been asked to provide advice outside of the PBL process is covered by the Law Officers’ Convention. This Convention provides that whether or not the Law Officers have been asked to provide advice, and the contents of any such advice, is not disclosed outside Government.
The Law Officers sit on the Parliamentary Business and Legislation Committee. As part of the process of approving a government Bill for introduction, as set out in the published Guide to Making Legislation, a legal issues memorandum is prepared for this Committee. This will set out all relevant legal issues.
Whether the Law Officers have been asked to provide advice outside of the PBL process is covered by the Law Officers’ Convention. This Convention provides that whether or not the Law Officers have been asked to provide advice, and the contents of any such advice, is not disclosed outside Government.
The information requested falls under the remit of the UK Statistics Authority.
Please see the letter attached from the National Statistician and Chief Executive of the UK Statistics Authority.
The Lord Kamall
House of Lords
London
SW1A 0PW
22 September 2025
Dear Lord Kamall,
As Acting National Statistician, I am responding to your Parliamentary Question asking what steps are being taken to improve the collection and publication of national data on drowning incidents, including demographic information, to inform targeted prevention policies (HL10639).
The Office for National Statistics (ONS) produces mortality statistics using information provided on death certificates. The ONS codes cause of death using the International Cause of Death (ICD-10). The ICD-10 codes for accidental drowning and submersion are W65 to W74.
The ONS publishes statistics on mortality by specific cause each year, in our Deaths
registered summary statistics [1]. Numbers of deaths for 2024 were published on 20 May 2025, and age-standardised mortality rates will be published on 9 October 2025. Table 3 in that publication presents deaths by specific causes, including accidental drowning and submersion, by sex and five-year age bands. Those published 2024 figures by age and sex are summarised with wider age bands in the table below.
The ONS is currently exploring methods to improve the timeliness of our mortality statistics. We launched a consultation earlier this year asking users about the value of reporting death occurrences rather than registrations for suicide statistics [2], and the same questions are being considered for wider mortality outputs too. This includes assessing the accuracy of “nowcasting”: estimating the number of recent death occurrences, by cause, using factors such as the number registered in the past week and trends in registration delays for that cause.
Death certification reform was also implemented in September 2024 [3], which included adding an ethnicity field to the death certificate for the first time in England and Wales. This aims to improve future reporting of deaths by ethnicity and will enable us to produce further demographic breakdowns in future.
Yours sincerely,
Emma Rourke
Table 1: Number of deaths registered by sex, age group and ONS short list of cause of death code, 2024, England and Wales
ICD-10 code | Underlying cause | Sex | All ages | Aged under 1 year | Aged 01 to 19 years | Aged 20 to 64 years | Aged 65 years and above |
W65 to W74 | Accidental drowning and submersion | Males | 213 | 1 | 23 | 129 | 60 |
W65 to W74 | Accidental drowning and submersion | Females | 83 | 1 | 12 | 38 | 32 |
Notes:
1. Figures are for deaths registered rather than deaths occurred. For more information see our Impact of registration delays publication [4].
2. Figures include non-residents.
3. Based on underlying cause of death.
4. The Office for National Statistics (ONS) short list for cause of death is based on a standard tabulation list developed by the ONS, in consultation with the Department of Health (now the Department of Health and Social Care, DHSC). For more information about the codes included, see our User guide to mortality statistics [5].
5. Figures for deaths aged under 1 year exclude deaths under 28 days, which are registered with separate neonatal death certificate from which it is not possible to assign an underlying cause of death. For more information see the childhood mortality section of our User guide to mortality statistics.
[1]https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/d eathsregisteredsummarystatisticsenglandandwales
[2]https://consultations.ons.gov.uk/external-affairs/user-requirements-for-official-suicide-statistics/
[4]https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/im pactofregistrationdelaysonmortalitystatisticsinenglandandwales/latest
[5]https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodolo gies/userguidetomortalitystatisticsjuly2017#ons-short-list-of-cause-of-death
The information requested falls under the remit of the UK Statistics Authority.
Please see the letter attached from the National Statistician and Chief Executive of the UK Statistics Authority.
The Lord Kamall
House of Lords
London
SW1A 0PW
21 March 2025
Dear Lord Kamall,
As National Statistician and Chief Executive of the UK Statistics Authority, I am responding to your Parliamentary Question asking for an estimate of the number of days of work that were lost due to asthma in the UK in each year since 2010 for which there are data available (HL5962).
The Office for National Statistics (ONS) collects information on the labour market status of individuals through the Labour Force Survey (LFS), which is a survey of people resident in households in the UK. The LFS also collects information on whether respondents have missed days off work due to illness and/or injury.
Unfortunately, we do not collect information regarding the type of sickness at a level of detail to identify those suffering from asthma specifically, but we can provide the number of working days lost due to respiratory conditions.
We publish estimates of the number of working days lost through sickness absence, including the number of working days lost due to respiratory conditions, in our Sickness absence in the UK labour market: 2022 article1. This article is due to be updated to include 2023 and 2024 estimates on 1 May 2025. This update will also include revisions to estimates from 2019 to 2022. We will send the updated data to you once it has been published.
Yours sincerely,
Professor Sir Ian Diamond
Table 1 contains LFS estimates of the number, and percentage, of working days lost due to respiratory conditions from 2012 to 2022, the latest data currently available.
Table 1: Number and percentage of working days lost due to respiratory conditions, between 2012 and 2022.
| Number of working days lost due to respiratory conditions (millions) | Percentage of working days lost due to respiratory conditions (% of all working days lost) |
2022 | 16.2 | 8.7 |
2021 | 10.0 | 6.7 |
2020 | 6.4 | 5.5 |
2019 | 5.6 | 4.0 |
2018 | 3.9 | 2.8 |
2017 | 3.7 | 2.8 |
2016 | 5.4 | 3.9 |
2015 | 5.4 | 3.9 |
2014 | 6.8 | 5.0 |
2013 | 5.8 | 4.4 |
2012 | 4.4 | 3.3 |
DBT, as part of the 2025 Autumn Budget announcements, launched a Call for Evidence on Business Support for Co-operatives and Mutuals. This was open across Great Britain for 12 weeks and closed on 18th February. DBT is now analysing responses and these responses will inform any potential business support policy for the co-operative and mutual businesses.
DBT ensured that for Financial Year 25/26 Growth Hubs in England offer support to businesses with alternative business models – including Co-operatives and Mutuals, as a condition of funding, and included more information on Co-operatives and Mutuals through the highly successful Help to Grow Management programme.
The Law Commission reviews are considering ways to update and modernise the legislation for co-operatives, community benefit societies, and friendly societies, ensuring that it fits the nature and needs of these societies as well as ensuring that regulation is proportionate and effective. The government will carefully consider the recommendations to understand whether reform is needed to ensure these businesses are supported to grow and succeed into the future.
The US has committed to ensuring that access to medicines and launches of new innovative medicines in the UK are not inadvertently impacted by the US’s ‘Most Favoured Nation’ policy, thereby reducing the risk to the UK where the NHS has managed to secure lower prices for medicines.
Further work to finalise underpinning details is ongoing.
Ministers and officials regularly meet with the Competition and Markets Authority to discuss key policy issues, including the CMA’s digital markets work. Close collaboration between Government and the CMA is crucial for delivering the agenda of this Government. As the UK’s independent competition authority, the CMA is responsible for all digital markets decisions, including on designations and interventions.
Ministers and officials have met with representatives of Google to discuss a range of topics, including the Competition and Markets Authority’s digital markets work. Such meetings are important for the exchange of views and the development of policy. As the UK’s independent competition authority, the CMA is responsible for all digital markets decisions, including on designations and interventions.
Next Steps to Make Work Pay, published in 2024, set out the Government’s preference for the statutory probation period to be nine months long.
Under the Employment Rights Bill, the normal grounds for fair dismissal (under the Employment Rights Act 1996) will apply in this period, and light-touch standards will apply to dismissals for reasons of the employee’s conduct, capability, illegality, or some other substantial reason relating to the employee. The Government believes this will allow businesses to remain confident in hiring.
The Digital Inclusion Innovation Fund was designed as a one-year programme to understand what works in digital inclusion, and how best practice or innovative approaches can be scaled to maximise local impact across the UK.
We remain committed to building a digitally inclusive society where no one is left behind, and plans for future support for digital inclusion are still in development.
We know that digital inclusion works best when it's delivered in local places by trusted people and organisations. The Digital Inclusion Innovation Fund is about backing local communities to close the digital divide, and grassroots organisations are fundamental to that process.
The Digital Inclusion Innovation Fund had 85 successful applications in England: a mix of charities, research organisations and local and combined authorities.
Around 73% of the organisations funded by the Digital Inclusion Innovation Fund are charities, many of which are local, grassroots voluntary organisations. We don't hold specific data on the annual income of organisations.
The GOV.UK app is in public beta with expenditure met from within the overall budgets of the Government Digital Service (GDS) as part of the wider GOV.UK modernisation activity.
In 25/26 c.£6.2m has been attributed to GOV.UK app and related programme of personalisation and modernisation - this relates to spend on design, build, test and running. There has been no significant spend on marketing of the app, with less than £2k related to reaching private beta testing audiences.
The Digital Inclusion Innovation Fund is about testing new ideas, learning what works, and supporting the best approaches so they can grow and benefit more communities across the UK. The Fund received 1016 applications from organisations across the country, amounting to a total request of over £170m for the £11.9m available.
Payment-in-arrears is the standard Government approach for grants. However, we recognise some stakeholders were concerned about payments-in-arrears and the short delivery window of the Fund. These issues are considerations we are taking forward as we continue policy development in this area.
Despite this, projects are continuing to deliver important outcomes for the people they support, such as supporting people to access the internet and building their digital skills.
We have appointed external evaluators who are working with grant recipients to understand the impact of the Fund. This will also involve assessing the process, including grant management and deliverability within the timescale.
We expect to receive their report in April 2026.
As of 16 March 2026, the GOV.UK App has an estimated total of over 230,000 active users. Analytics tracking captures only those who opt in, so this figure is higher than the number of users providing consent. To date, approximately 135,000 users have consented to analytics tracking, averaging around 23,000 consented users per month.
While the Government has not set formal numerical targets for 2026–27, the strategic aim is to drive sustained growth by making the GOV.UK App the most convenient and trusted way for people to access government services. Growth is expected as new features and services are introduced, alongside improvements in personalisation and ongoing focus on user needs, in line with the Government Digital Service’s roadmap for modern digital government.
The Government is also committed to addressing digital exclusion. The GOV.UK App has been designed to be simple and accessible, informed by user research conducted during its public beta and in line with GOV.UK accessibility standards. Alongside this, the Government will continue to assess the digital skills support needed, including understanding barriers faced by digitally excluded groups and working with departments, local authorities and delivery partners to provide assisted digital support and signposting to digital skills training. Services will continue to be available through multiple channels, ensuring that those who are unable to use digital services can still access government support.
The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), is not currently funding any research into vaccines for gingivitis or periodontitis. MRC invests more broadly in dental and oral health research, including some periodontitis research, to aid its detection and treatment.
Ofcom will set out what technology is required for a service to comply with a Technology Notice under section 121 of the Online Safety Act. That technology must be accredited as meeting minimum standards of accuracy. Ofcom’s consultation on the minimum standards of accuracy closed in March 2025 and the finalised version will be published in due course.
Where a tech solution does not exist in relation to a particular service design, Ofcom will be able to direct companies to use best endeavours to develop or source technology that deals with child sexual exploitation and abuse content.
Digital inclusion is a priority for this Government. It means ensuring that everyone has the access, skills, support and confidence to participate in our modern digital society, whatever their circumstances. Work is ongoing to develop our approach to tackling digital exclusion and coordinating across government departments continues to be a core part of this work. We hope to say more on this soon.
The Reducing Drug Deaths Innovation Challenge funded eleven technologies in its first phase, all of which were completed successfully. Seven projects secured phase 2 funding to advance development of their technologies through testing with relevant populations. The UK Government’s Office for Life Sciences, in collaboration with the Chief Scientist Office in Scotland, is monitoring the progress of these projects and will provide guidance to support commercialisation, spread and UK-wide adoption of the technologies to prevent drug overdose deaths. Future funding and initiatives through the Addiction Healthcare Goals programme are being explored to further encourage innovative research and the development of novel technologies to treat drug and alcohol addictions.
While no such assessment has been made, this Government recognises the importance of exploring innovative approaches to tackle loneliness, whilst protecting people's safety and wellbeing.
Collaboration and partnership are at the heart of the Civil Society Covenant which was launched by the Prime Minister in July at a major civil society summit. To inform the development of the Civil Society Covenant, the Department for Culture, Media and Sport engaged with over 1,200 organisations and worked closely with the Civil Society Advisory Group, including representatives from the National Council for Voluntary Organisations (NCVO) alongside a wide range of other civil society organisations.
At the launch we announced the Joint Civil Society Covenant Council which will be central to the delivery of the Covenant, setting direction and providing strategic oversight for its implementation. It will have cross-sector membership comprising senior leaders from civil society and senior representatives from government departments. We also announced a Local Covenant Partnerships Programme to support collaborative working between civil society organisations, local authorities and public service providers to deliver services that better meet the needs of their communities.
We will continue working in the spirit of partnership as we establish and develop both the Joint Civil Society Covenant Council and the Local Covenant Partnerships Programme.
Collaboration and partnership are at the heart of the Civil Society Covenant which was launched by the Prime Minister in July at a major civil society summit. To inform the development of the Civil Society Covenant, the Department for Culture, Media and Sport engaged with over 1,200 organisations and worked closely with the Civil Society Advisory Group, including representatives from the National Council for Voluntary Organisations (NCVO) alongside a wide range of other civil society organisations.
At the launch we announced the Joint Civil Society Covenant Council which will be central to the delivery of the Covenant, setting direction and providing strategic oversight for its implementation. It will have cross-sector membership comprising senior leaders from civil society and senior representatives from government departments. We also announced a Local Covenant Partnerships Programme to support collaborative working between civil society organisations, local authorities and public service providers to deliver services that better meet the needs of their communities.
We will continue working in the spirit of partnership as we establish and develop both the Joint Civil Society Covenant Council and the Local Covenant Partnerships Programme.
Swimming and water safety are vital life skills that are compulsory elements of the PE National Curriculum at key stages 1 and 2. In addition, the changes made to the department’s statutory relationships, sex and health education guidance will ensure all pupils are taught about the water safety code, supporting them to be safe in different types of water. To support schools, Oak National Academy offers swimming and water safety units as part of its PE curriculum, developed in partnership with Swim England.
In June, my right hon. Friend, the Prime Minister announced a new national approach to PE and school sport as part of which we will establish a PE and School Sport Partnership Network, designed to build stronger links between schools, local clubs, and National Governing Bodies. It will identify and remove barriers to participation in PE and school sport, including swimming.
The department is also providing a grant of up to £300,000 to deliver Inclusion 2028, a programme which upskills teachers to deliver high quality, inclusive PE, including swimming and water safety, to pupils with special educational needs and disabilities.
Skills England, and its predecessor the Institute for Apprenticeships and Technical Education (IfATE), has worked with employers to develop apprenticeships covering a range of occupations in the care services sector. These are designed to enable an individual to acquire full competence in an occupation whilst undertaking paid work and provide a progression route in the sector. These products are available for both public and private sector employers to use, with funding to support the training from the Growth and Skills Levy.
In addition, a Health and Social Care foundation apprenticeship has been developed and will be available for delivery from autumn this year. This is specifically aimed at young people who are not yet ready for work, and will provide the individual with a mix of employability and sectoral skills designed to provide a good grounding for a career in the health or adult social care sector.
To support the awareness of careers in adult social care, the National Careers Service, a free, government funded careers information, advice and guidance service, uses a range of labour market information to support and guide individuals. The Service website gives customers access to a range of digital tools and resources, including ‘Explore Careers’ which includes more than 130 industry areas and more than 800 job profiles including a range of construction and health and social care roles, describing what the roles entail, qualifications needed and entry routes.
As part of the UK-EU SPS Agreement currently being negotiated, the Government is making a sovereign choice in the national interest to align in some areas where it makes sense to do so, as set out in the Government’s recently published announcement on legislation in scope. This includes Regulation 1925/2006 on the addition of vitamins and minerals and certain other substances to foods and Directive 2002/46/EC relating to Food supplements. While those negotiations are ongoing, we cannot comment further on the SPS agreement.
The Government is committed to working with industry, particularly those impacted on the above, on preparing for implementation, noting that the precise detail and timing of this process – including legislative arrangements are subject to discussions with the EU.
The Government is currently negotiating a Sanitary and Phytosanitary Agreement to make agrifood trade with our biggest market cheaper and easier, cutting costs and red tape for British producers and retailers, and helping to reduce the pressure on prices and increase choice in the shops.
We are working closely with businesses to assess the implementation impacts of the Agreement.
We have begun negotiations with the EU on an SPS agreement to make agrifood trade with our biggest market cheaper and easier, cutting costs and removing barriers to trade for British producers and retailers. While negotiations with the EU on the SPS agreement are underway, we will not be providing a running commentary of discussions.
The size of the probiotics market in the United Kingdom was £1.07 billion in 2024 (table 1, Euromonitor International*). The UK market value for probiotic products grew by 19% between 2019 and 2024 (in 2024 prices) and 41% by sales volumes. Recent growth in the probiotic market has been attributed to the increasing popularity of probiotic dairy products like Kefir.
Table 1 – UK probiotic product retail sales (GBP million, Euromonitor)
Category | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Probiotic Dairy | 690.8 | 780.0 | 867.5 | 949.6 | 999.5 | 1,051.8 |
Probiotic Butter and Spreads | 7.3 | 7.3 | 8.0 | 9.8 | 11.1 | 10.6 |
Probiotic Other Dairy | 4.9 | 5.8 | 5.5 | 7.5 | 7.5 | 10.1 |
Probiotic Snacks | 0.5 | 0.7 | 3.4 | 1.5 | 1.1 | 1.8 |
Probiotic Carbonates | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.6 |
Probiotic Cheese | 1.6 | 1.4 | 0.0 | 0.0 | - | 0.0 |
Total UK Market | 705.3 | 795.5 | 884.7 | 968.7 | 1,019.5 | 1,074.9 |
Euromonitor have considered growth in the wider UK diary and dairy alternatives market and forecast that the value of probiotic dairy market will grow by 14% up to 2029, to £1.2 billn. There is no forecast for the overall probiotics market, but as probiotic dairy products make up 99% of the market by volume, this forecast is sufficient for the market overall.
*Although Euromonitor aims to correct inaccuracies of which it is aware, it does not warrant that the Intelligence will be accurate, up-to-date or complete as the accuracy and completeness of the data and other content available in respect of different parts of the Content will vary depending on the availability and quality of sources on which each part is based. Euromonitor accepts no liability in regard to the derived data which has been presented here and furthermore, Euromonitor does not warrant that the Intelligence will be/is fit for any particular purpose(s) for which they are used as Euromonitor does not have any knowledge of, nor control over, those purposes.
Responsibilities for water safety sit with various Government departments, agencies, local authorities, and other public bodies. These include regular safety messaging and guidance to ensure people have the knowledge they need to keep themselves safe, as well as provision of safety/lifesaving equipment at water bodies. Water sports national governing bodies are responsible for providing advice and guidance for how to participate in their sports safely. Inland waterway navigation authorities conduct risk assessments to inform the provision of appropriate lifesaving equipment on their networks. In conjunction with other services, HM Coastguard provides safety advice and guidance about the coastal environment.
The National Water Safety Forum brings together a wide range of national groups, including some 80 local authorities, to create a ‘one-stop shop’ for the prevention of drowning and water safety harm in the UK. The Forum launched the UK Drowning Prevention Strategy 2016-2026 (copy attached), which aims to reduce the number of accidental drownings in the UK by 50% by 2026. The Local Government Association has developed a water safety toolkit (copy attached) for local authorities for use inland and on the coast.
The Government oversees policy and legislation with respect to the safe management of waste and litter as well as the protection of drains and sewers. This however does not extend to compelling or explicitly encouraging local authorities with regard to types of waste receptacles or their placement. These decisions are for local authorities to make.
The Building Regulations for England were updated in 2024 with the addition of a new ‘Part T’ which sets out toilet requirements in new non-domestic buildings in England. Part T is supported by statutory guidance which includes space for disposal bins in the design layouts. However, the Building Regulations are limited to the provision and design of toilet facilities and do not extend to the management and use of disposal bins.
The Health and Safety Executive (HSE) is reviewing the Approved Code of Practice (ACOP) and the guidance of the Workplace (Health, Safety and Welfare) Regulations 1992 regarding the provision of disposal facilities in workplace toilets. This work is included within the Government’s wider plans under Make Work Pay, and HSE will hold appropriate consultation in due course.
I refer the hon. Member to the reply previously given on 20 January 2025, PQ HL3929, as no further discussions with Ofwat or water companies have taken place since.
The Government recognises that rainwater harvesting and other forms of water reuse can play a key role in helping non-households and businesses meet the statutory water demand reduction target of 9% by March 2038. We are therefore supporting water companies and developers to deliver water efficiency through both rainwater harvesting and other forms of water reuse.
We supported Ofwat on their consultation to provide environmental incentives to developers which included considering where new technologies and water efficient practices could be integrated into buildings and developments. Ofwat reported that water reuse solutions are likely to be an important tool for improving water efficiency in the medium term.
We are also looking into allowing water companies to supply treated, non-potable water, including rainwater, for certain water demands such as toilet flushing.
Through the next phase of Keep Britain Working we will work with businesses of all sizes to design solutions which support the health and wellbeing of employees across the UK. Through employer-led sprints, we are developing a Healthy Working Lifecycle Standard, tailored workplace health support, and stronger evidence on the business benefits of investing in employee wellbeing.
Our Vanguard group includes over 120 employers of varying sizes to ensure the approaches developed reflect the needs and realities of both large employers and SMEs. We are also working closely with regional authorities and leadership to connect the programme to smaller employers across the country.
During the Keep Britain Working review, we heard that employers are already bearing the cost of sickness absence and employees leaving the workforce and are therefore highly incentivised to support the health and wellbeing of their employees. Through the next phase of Keep Britain Working we will grow the evidence for what works and where additional incentives could have the greatest impact, ensuring that support is targeted in ways that encourage employers to take-up effective workplace health measures.
The Government is committed to improving vaccine uptake and access across all immunisation programmes by exploring new and innovative delivery models, including expanding routes such as community pharmacies, as set out in the NHS Vaccination Strategy and the 10-Year Health Plan for England.
The Department is working with the UK Health Security Agency and NHS England to develop options for delivering human papilloma virus catch-up vaccination through community pharmacies, with the ambition to increase uptake among younger adults who have left school, supporting our aim to eliminate cervical cancer by 2040. Further guidance on roll-out plans will be published in due course.
The NHS Vaccination Strategy aims to increase uptake across the population, particularly in underserved groups, through more accessible, locally delivered services supported by national consistency in standards and digital systems. It promotes convenient access through primary care and community settings, alongside a more integrated approach where multiple vaccinations and wider health interventions can be offered together. Specific actions already delivered under the NHS Vaccination Strategy to improve the vaccination offer include the following:
These measures demonstrate clear progress towards a more joined-up prevention and vaccination offer for local populations, particularly through local commissioning, broader delivery models, and digital capability. As many of these initiatives remain in development, the full extent of their impact is still emerging.
Building on this, the 10-Year Health Plan reinforces the shift towards prevention and digital access, including expanding the role of community pharmacies, introducing new delivery models for underserved groups, and improving access through the NHS App.
The UK Health Security Agency (UKHSA) works with partners in NHS England to process, validate, and publish new data, where available, to improve monitoring of national vaccine programmes through the publication of reliable statistics. UKHSA constantly undertakes reviews of the quality and timeliness of the data published, assessing the quality of the source data against the data quality dimensions in The Government Data Quality Framework, publishing quality and methodology reports alongside the data reports.
The Government Data Quality Framework, the Respiratory syncytial virus (RSV) QMI report, which outlines the quality and methodology information relevant to the RSV official statistics releases, and the Quality and methodology information: human papillomavirus (HPV) vaccine coverage estimates in England are all available on the GOV.UK website.
It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.
In April 2025, NHS England’s Getting It Right First Time programme introduced a nationally standardised eight-week treatment pathway for patients with severe aortic stenosis, which is an advanced heart valve disease. This system-level reform targets persistent delays between diagnosis and intervention for aortic stenosis, to reduce emergency admissions.
To improve awareness of heart valve disease in primary care and to aid in diagnosis, NHS England commissioned the Primary Care Cardiovascular Society in 2024 to develop a referral form to support the investigation of heart valve disease.
The National Cancer Plan, published in February 2026, announced that £200 million in 2026 to 2027 has been ring fenced for Cancer Alliances to support them in making sustainable improvements to cancer delivery, as part of system development funding (SDF).
Cancer SDF comprises of two allocations: place-based, which is provided to all Alliances on a fair-shares basis for local population needs; and targeted, which is provided to Alliances for targeted projects, with amounts determined by agreed run rates. Cancer Alliances must demonstrate how their spending reduces disparities and improves access to care.
Monthly inpatient procedure data is published regularly as part of the Hospital Episode Statistics for Admitted Patient Care, Outpatient and Accident and Emergency dataset. The number of finished consultant episodes with a procedure from January 2024 to February 2026 is included in the table below. Whilst the data is published, it is provisional and may be incomplete or contain errors for which no adjustments have yet been made. Counts produced from provisional data are likely to be lower than those generated for the same period in the final dataset. This shortfall will be most pronounced in the final month of the latest period, in this case February 2026. The following table shows the number of inpatient finished consultant episodes for each month from 2024 to February 2026:
Month | Finished consultant episodes with a procedure |
February 2026 | 688,599 |
January 2026 | 1,081,294 |
December 2025 | 1,051,403 |
November 2025 | 1,082,788 |
October 2025 | 1,184,030 |
September 2025 | 1,151,112 |
August 2025 | 1,078,412 |
July 2025 | 1,195,585 |
June 2025 | 1,141,939 |
May 2025 | 1,148,930 |
April 2025 | 1,113,620 |
March 2025 | 1,124,068 |
February 2025 | 1,066,024 |
January 2025 | 1,162,743 |
December 2024 | 1,051,251 |
November 2024 | 1,142,324 |
October 2024 | 1,201,633 |
September 2024 | 1,117,229 |
August 2024 | 1,117,522 |
July 2024 | 1,187,835 |
June 2024 | 1,090,901 |
May 2024 | 1,155,607 |
April 2024 | 1,120,946 |
March 2024 | 1,071,637 |
February 2024 | 1,064,516 |
January 2024 | 1,116,786 |
Source: Provisional Monthly Hospital Episode Statistics for Admitted Patient Care, Outpatient and Accident and Emergency data, NHS England.
No formal assessment has currently been made on the contribution of robotic-assisted procedures to achieving the March 2026 target of 65% of patient pathways waiting less than 18 weeks to start first treatment.
The Elective Reform Plan, January 2025, outlined the productivity and modernisation efforts needed to restore 18-week referral-to-treatment standards. We will continue to utilise widespread advances in techniques and technology, including robotic surgery to deliver higher quality care sooner. In February 2026, performance against the standard for 92% of patients to start first treatment within 18 weeks of referral was 62.6%, 3.4% higher than a year earlier.
Data on the current waiting list for pathways involving robotic procedures is not held in the format requested.
The Office for National Statistics’ mortality data comes from the information collected at death registration on death certificates and would be the most accurate source for the information. For this reason, the Department has not made an assessment of the number of deaths from anorexia nervosa.
However, the Government shares concerns about the accurate recording of deaths, including when eating disorders may have been a contributing factor. The statutory medical examiner and coroner systems provide a clear framework to ensure deaths are appropriately investigated and recorded, so that lessons are identified and patient safety is strengthened.
Ultimately, the Ministry of Justice owns coroner policy, and it is for the coroner, exercising independent judicial discretion, to determine what is recorded on the medical cause of death.
Accurate recording does matter, and we will continue to work with partners, including colleagues at the Ministry of Justice, to ensure that learning is captured and reflected in improvements to care.
The Department and NHS England are working with senior leaders across the health system, including integrated care boards (ICBs), to make sure that procurement of surgical robotic platforms supports innovation, transparency and long-term value.
No guidance has been provided to ICBs at this stage, but equity of access remains a key consideration. The Department and NHS England are working with regional partners to understand how robotics can be deployed in a way that supports equity, productivity and population need. Regional alliances refer to Cancer Alliances, which look at the care and support patients should expect to receive from diagnosis to follow-up across their whole area, so they can address variation and implement best practice. NHS England provides Cancer Alliances with funding for cancer to assist in their work.
Decisions on the procurement of robotic-assisted surgery are made locally by National Health Service trusts and ICBs, in line with local need and national guidance. No specific targets or monitoring arrangements have been set in relation to uptake or implementation of the July 2025 Getting It Right First Time (GIRFT) guidance. However, a baseline assessment is being undertaken to understand the current provision of robotic assisted surgery and the increase in activity needed to begin to close the gaps. NHS England has funding in place for a national robotic surgery registry, which, once established will provide near real-time data on this aspect.
The NHS Payment Scheme (NHSPS) and the National Commissioning model for high cost, high impact medical devices look to review the appropriate commissioning model for such devices. They ensure patients can access clinically effective high-cost devices, while maintaining consistency across England and ensuring the responsible use of public funds. They are kept under constant review to ensure it reflects clinical evidence, innovation, and National Health Service priorities.
Where devices are particularly high cost, clinically specialised, or used only for defined patient groups, they may be excluded from the national tariff. High-cost device exclusions are kept under regular review by NHS England as part of the annual NHSPS development process. Where a device becomes more routinely used, its cost reduces, or it can reasonably be absorbed into standard prices, NHS England may consider removing the exclusion and bundling the device into the national tariff. Conversely, exclusions may be introduced where new technologies are high cost, used for limited patient cohorts, or present material financial risk. Any proposed changes are consulted on publicly and confirmed through publication of the NHSPS.
Some high-cost devices are also subject to NHS England’s Specialised Services Devices Programme. This applies to devices used in specialised services that are commissioned nationally, often for patients with complex or rare conditions. The programme provides a structured process to assess clinical effectiveness, patient benefit, affordability, and system impact before devices are routinely commissioned. Where approved, NHS England may introduce national commissioning policies, central procurement arrangements, or national pricing agreements, with funding aligned to specialised commissioning while operating alongside the NHSPS.
For devices not covered by either national prices or exclusions, the NHSPS allows local pricing agreements, provided these adhere to national pricing rules and principles on efficiency, transparency, and value for money.
Through the National Cancer Plan for England, the Government is committing up to £10 million a year to a new fund open to all children and young people in England with cancer and their families regardless of income, to support them with the cost of travelling to and from their treatment. This commitment sits alongside wider action to transform cancer care for children and young people.
The Department is currently working with its partners to define the scope and parameters of the scheme and further detail will be announced in due course.
Currently, the National Health Service runs schemes in England to provide financial assistance for travel to a hospital or other NHS premises for specialist treatment or diagnostics tests, following referral from a primary healthcare professional. The Healthcare Travel Costs Scheme provides financial assistance to patients in England who do not have a medical need for transport, but who require assistance with the costs of travelling to receive certain NHS services. The Non-Emergency Patient Transport Services provide funded transport where it is considered essential to ensuring an individual’s safety, safe mobilisation, condition management, or recovery.
Whether a device category is excluded from tariffs and within the commissioning responsibility of NHS England is not determined by the Specialised Services Devices Programme (SSDP).
Any individual can nominate a device or device category to be excluded from tariffs. The description of this annual nomination process can be found on the NHS.UK website. Once this process is completed, feedback is shared with the person who has made the nomination. Inclusion on the High Cost Devices tab within the NHS Payment Scheme Workbook with the commissioning responsibility identified as NHS England indicates that a device category is included on SSDP.
In line with contractual terms included within the NHS Standard Contract, all devices eligible for reimbursement must be purchased through NHS Supply Chain. Therefore, all products reimbursed must also be eligible for purchase through this route. Individual devices agreed for reimbursement are assessed by SSDP, working with NHS Supply Chain and frontline clinicians using a process which has been widely communicated to industry suppliers and was extensively tested with the Association of British Healthtech Industry. This process considers a number of factors, including high quality clinical evidence, comparative costs, and affordability. This process supports suppliers to provide information and evidence in a consistent format for further evaluation. There is an intention to publish this process on the NHS England website.
The Department invests over £1.7 billion each year on research through the National Institute for Health and Care Research (NIHR). In December 2025, the NIHR announced an initial £13.7 million investment in the Brain Tumour Research Consortium. In January 2026, the NIHR announced further investment of a minimum of £11.7 million in the consortium through funding of work packages. This brings the total investment to over £25 million.
The exact amount paid as of March 2026 is £50,000, which was paid to the contractor on 31 December 2025. This payment was made to support start up activities for the consortium. The NIHR does not currently hold up-to-date expenditure, or a detailed breakdown of how this funding has been spent. This information is currently held by the research team of the NIHR Brain Tumour Research Consortium and will be provided to the NIHR in the future as part of the project’s annual financial returns.
For all awards, contracting and further payments are contingent upon teams submitting and reviewing detailed costs and, if applicable, agreeing to the suggested amendments and requests for clarification which are currently in progress.
Future payments will be issued over the period of the award contracts, which range from five to 10 years, as per the schedule of payments agreed between the NIHR and the consortium.
Information on all awards will be made publicly available in due course. The NIHR is working to ensure that new investments can get up and running as soon as possible. Oversight of the Brain Tumour Research Consortium is the responsibility of the NIHR.
In addition, the NIHR continues to strongly encourage brain cancer research applications through its regular funding opportunities.
The National Cancer Plan, published on the 4 February 2026, sets out several commitments and ambitions, to be delivered within the next 10 years. The role of the reformed National Cancer Board will be to support and monitor the delivery of the commitments and ambitions and provide regular updates to ministers.
To hold us accountable across these commitments, and to drive forward progress for rare cancer patients, we will appoint a National Clinical Lead for Rare Cancers, who will provide independent advice on improving outcomes.
Until the appointment is made, NHS England’s Clinical Advisory Group has leads for specific rare cancers to provide NHS England and the Department with clinical advice. Professor Lucy Chappell, the Department’s Chief Scientific Adviser, is the Chief Executive Officer for the NIHR.
The Department invests over £1.7 billion each year on research through the National Institute for Health and Care Research (NIHR). In December 2025, the NIHR announced an initial £13.7 million investment in the Brain Tumour Research Consortium. In January 2026, the NIHR announced further investment of a minimum of £11.7 million in the consortium through funding of work packages. This brings the total investment to over £25 million.
The exact amount paid as of March 2026 is £50,000, which was paid to the contractor on 31 December 2025. This payment was made to support start up activities for the consortium. The NIHR does not currently hold up-to-date expenditure, or a detailed breakdown of how this funding has been spent. This information is currently held by the research team of the NIHR Brain Tumour Research Consortium and will be provided to the NIHR in the future as part of the project’s annual financial returns.
For all awards, contracting and further payments are contingent upon teams submitting and reviewing detailed costs and, if applicable, agreeing to the suggested amendments and requests for clarification which are currently in progress.
Future payments will be issued over the period of the award contracts, which range from five to 10 years, as per the schedule of payments agreed between the NIHR and the consortium.
Information on all awards will be made publicly available in due course. The NIHR is working to ensure that new investments can get up and running as soon as possible. Oversight of the Brain Tumour Research Consortium is the responsibility of the NIHR.
In addition, the NIHR continues to strongly encourage brain cancer research applications through its regular funding opportunities.
The National Cancer Plan, published on the 4 February 2026, sets out several commitments and ambitions, to be delivered within the next 10 years. The role of the reformed National Cancer Board will be to support and monitor the delivery of the commitments and ambitions and provide regular updates to ministers.
To hold us accountable across these commitments, and to drive forward progress for rare cancer patients, we will appoint a National Clinical Lead for Rare Cancers, who will provide independent advice on improving outcomes.
Until the appointment is made, NHS England’s Clinical Advisory Group has leads for specific rare cancers to provide NHS England and the Department with clinical advice. Professor Lucy Chappell, the Department’s Chief Scientific Adviser, is the Chief Executive Officer for the NIHR.